Cosmetic study results buoy Syntopix

from ShareCast

LONDON (SHARECAST) - AIM Listed dermatological drug developer Syntopix has announced positive results from its phase II cosmetic study in subjects with acneic skin, it said today. A Syntopix product reduced the total number of acne spots to a significantly greater extent from week 4 onwards than a currently marketed acne treatment, said the group. The study, which began in July 2007, was conducted in Germany and investigated the Syntopix preparations SYN 0126, a compound used in cosmetic preparations, and a combination of SYN 0126 with SYN 0091, a bacteriostatic agent used in soaps and cosmetics. The company now intends to investigate the possibility of a licensing agreement with a suitable partner in the cosmetics or consumer healthcare industries.